Contents

Volume 80 Issue 1 | ARD January 2021

Editorials

1 Greetings from the editor 2021
J S Smolen

3 COVID-19 cytokine storm: what is in a name?
P A Nigrovic

Views on news

6 The role of TSLP in the pathogenesis of SLE: X marks the spot
D S Pitsakis

Heroes and pillars of rheumatology

8 Jan Mikulicz-Radecki (1850–1905): return of the surgeon
B Manger, G Schett

Thinking the unthinkable

11 Publishing in 2@84
M Lanzilla, C Creti, V M Da Silva Domingues, K Lauper, G R Burmester

Review

14 Update on the diagnosis and management of systemic lupus erythematosus
A Fautrel, N Tsibos, G Berrias, D T Boumpas

Viewpoint

26 Trajectories of COVID-19 information in the Annals of the Rheumatic Diseases: the first months of the pandemic
K Lauper, J W Bijlsma, G R Burmester

Recommendations

31 EULAR definition of difficult-to-treat rheumatoid arthritis

49 EULAR recommendations for a core data set for pregnancy registries in rheumatology

57 2019 EULAR points to consider for non-physician health professionals to prevent and manage fragility fractures in adults 50 years or older

65 2019 EULAR points to consider for the assessment of competencies in rheumatology specialty training

71 Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
## Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>88</td>
<td>Preliminary predictive criteria for COVID-19 cytokine storm</td>
</tr>
<tr>
<td>103</td>
<td>Rheumatoid arthritis (Summary)</td>
</tr>
<tr>
<td>109</td>
<td>Systemic lupus erythematosus (Summary)</td>
</tr>
<tr>
<td>118</td>
<td>Systemic sclerosis (Summary)</td>
</tr>
<tr>
<td>128</td>
<td>Autoinflammatory disorders</td>
</tr>
<tr>
<td>134</td>
<td>Letter</td>
</tr>
<tr>
<td>e1</td>
<td>Electronic pages</td>
</tr>
<tr>
<td>e2</td>
<td>Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India</td>
</tr>
<tr>
<td>e3</td>
<td>The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capechi et al</td>
</tr>
<tr>
<td>e4</td>
<td>Online management of rheumatoid arthritis during COVID-19 pandemic</td>
</tr>
</tbody>
</table>

### Rheumatoid arthritis
96 Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study

### Systemic lupus erythematosus
109 Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing

### Systemic sclerosis
118 Genomic Risk Score impact on susceptibility to systemic sclerosis

### Autoinflammatory disorders
128 Fast diagnostic test for familial Mediterranean fever based on a kinase inhibitor

### Letter
134 Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corona RA registry
K L Winthrop, G Citera, D Gold, D Hentz, C A Connell, A B Shapiro, H Shi, A M Onufri, D A Pappas, H Schultze-Koops

### Electronic pages

- **e1** Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India
  - L Gupta, D P Misra, V Agarwal, S Balan, V Agarwal

- **e2** Antirheumatic agents in covid-19: is IL-6 the right target?
  - P L Capecci, P E Lazzerini, L Volterrani, M A Mazzetti, B Rossetti, G Zanelli, D Bennett, E Bargagli, F Franci, M Cameli, S Valente, L Contarini, B Frediani

- **e3** The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: ‘Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India’ by Gupta et al and ‘Antirheumatic agents in covid-19: is IL-6 the right target?’ by Capecci et al
  - S Monti, C Montecucco

- **e4** Online management of rheumatoid arthritis during COVID-19 pandemic
  - Y Zhang, J Wang, L Zhao, J Xiao, Z Shi

- **e5** Challenges and opportunities in teleheumatology in the COVID-19 era. Response to: ‘Online management of rheumatoid arthritis during COVID-19 pandemic’ by Zhang et al
  - G Figueras-Purra, C M Gamboa-Alonso, D A Galarza-Delgado
e6  Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?
   W Xie, Y Wang, Z Zhang

e7  Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: ‘Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?’ by Xie et al
   C M Gamboa-Alonso, G Figueras-Parra, D A Galarza-Delgado

e8  To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic
   K Parperis

e9  Response to ‘To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic’ by Parperis
   F R Spinelli, F Ceccarelli, M Di Franco, F Conti

e10 Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia
    P Guilpain, C Le Bihan, V Foulongne, P Taourel, N Pansu, A T J MARIA, B Jung, R Larcher, K Klouche, V Le Moing

    S Monti, C Montecucco